1334513-02-8 Usage
Description
N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester is a complex organic compound with a unique chemical structure. It is characterized by its fluorinated phenoxy group and phosphinyl linkage, which contribute to its reactivity and potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-alanine 1-Methylethyl ester is used as a reactant for the synthesis of phosphoramidate imidazo[2,1-f][1,2,4]triazine-4-amine adenosine prodrugs. These prodrugs are designed to enhance the anti-HCV (hepatitis C virus) activity, providing a potential therapeutic approach for treating hepatitis C infections.
Check Digit Verification of cas no
The CAS Registry Mumber 1334513-02-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,4,5,1 and 3 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1334513-02:
(9*1)+(8*3)+(7*3)+(6*4)+(5*5)+(4*1)+(3*3)+(2*0)+(1*2)=118
118 % 10 = 8
So 1334513-02-8 is a valid CAS Registry Number.
InChI:InChI=1S/C18H17F5NO5P/c1-9(2)27-18(25)10(3)24-30(26,28-11-7-5-4-6-8-11)29-17-15(22)13(20)12(19)14(21)16(17)23/h4-10H,1-3H3,(H,24,26)/t10-,30?/m0/s1
1334513-02-8Relevant articles and documents
Nucleotide derivative and pharmaceutical composition and application thereof
-
Paragraph 0165; 0168-0169; 0171, (2021/08/25)
The invention discloses a nucleotide derivative and a pharmaceutical composition and application thereof, wherein the nucleotide derivative is as shown in a formula (I). The compound can be used for preparing anti-virus infection drugs.
PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER
-
Paragraph 00134-00135, (2021/03/05)
There are provided compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, useful for inhibition or modulation of the activity of tyrosine kinases and treatment of disease states or conditions mediated by tyrosine kinases, including cancers. (I)
Method for preparing sofosbuvir intermediate by using microfluid reaction device
-
Paragraph 0046-0054, (2020/04/17)
The invention discloses a method for preparing a sofosbuvir intermediate by using a microfluid reaction device. The method comprises the following steps: pumping phenyl dichlorophosphate and pentafluorophenol into a first micro-channel reactor, carrying o